| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
Form 4: Goncalves Joana, Chief Medical Officer
Received 7,000 shares by exercise or conversion ($51.2K) · Sold 7,000 shares ($707K) |
| 16 Nov 2026 | SCHEDULE 13G |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 |
Form 4: Agarwal Arjun, Senior Vice President, Finance
Received 10,000 shares by exercise or conversion ($157K) · Sold 10,000 shares ($1.05M) |
| 13 Nov 2026 |
Form 4: Ball Kristine M, Director
Received 18,000 shares by exercise or conversion ($123K) · Sold 18,000 shares ($1.89M) |
| 12 Nov 2026 | 144 |
| 12 Nov 2026 | 144 |
| 09 Nov 2026 | QUARTERLY REPORT |
| 02 Nov 2026 |
Form 4: Klein Lawrence Otto, Director
Received 25,000 shares by exercise or conversion ($195K) · Sold 25,000 shares ($2.39M) |
| 02 Nov 2026 | 144 |
| 26 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
©2026 Oruka Therapeutics ©2026 ORUKA THERAPEUTICS EVERLAST - B Interim Data ORKA - 001 Phase 2b trial in psoriasis October 26, 2026 |
| 20 Oct 2026 |
Form 4: Quinlan Paul T, General Counsel
Received 9,000 shares by exercise or conversion ($70.2K) · Sold 9,000 shares ($707K) |
| 15 Oct 2026 |
Form 4: Goncalves Joana, Chief Medical Officer
Received 7,000 shares by exercise or conversion ($51.2K) · Sold 7,000 shares ($524K) |
| 15 Oct 2026 | 144 |
| 13 Oct 2026 |
Form 4: Agarwal Arjun, Senior Vice President, Finance
Received 9,999 shares by exercise or conversion ($157K) · Sold 9,999 shares ($806K) |
| 13 Oct 2026 | 144 |
| 02 Oct 2026 |
Form 4: Klein Lawrence Otto, Director
Received 25,000 shares by exercise or conversion ($195K) · Sold 25,000 shares ($2.09M) |
| 01 Oct 2026 | 144 |
| 21 Sep 2026 |
Form 4: Agarwal Arjun, Senior Vice President, Finance
Sold 533 shares ($51K) |
| 21 Sep 2026 |
Form 4: Quinlan Paul T, General Counsel
Received 10,000 shares by exercise or conversion ($78K) · Sold 10,000 shares ($936K) |
Loading...